Drug Abuse Aspects of Hiv/Aids and Other Infections

The summary for the Drug Abuse Aspects of Hiv/Aids and Other Infections grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Drug Abuse Aspects of Hiv/Aids and Other Infections: The National Institute on Drug Abuse (NIDA) supports research on the natural history, epidemiology, etiology, virology and pathogenesis, prevention, and treatment of drug abuse and drug abuse aspects of HIV/AIDS and other infectious agents [e.g., hepatitis B virus (HBV), hepatitis C virus (HCV), other sexually transmitted infections (STIs), and tuberculosis (TB)]. AIDS was first recognized as a growing epidemic among men who have sex with men (MSM) and injection drug users (IDUs) and their sexual partners in the early 1980s. While considerable scientific progress has been made since then in understanding, preventing, and treating the intertwined epidemics of drug abuse and HIV/AIDS, much remains unknown or poorly understood today. Emerging drugs of abuse, such as the club drugs ecstasy (MDMA), GHB, ketamine, and methamphetamine, as well as more potent supplies of heroin, cocaine, and marijuana, are continually changing the profiles of populations at risk. Moreover, these drugs often contain adulterants, and are used in risky social contexts in combination with alcohol and other drugs, including Viagra, poppers, and tobacco. In the United States today, over 77,000 women have been diagnosed with AIDS attributed to injection drug use or sex with an IDU, and nearly a third of AIDS cases in adult/adolescent women diagnosed in 2001 reported injection drug use or sex with an IDU as their primary risks. Racial and ethnic minority populations of both genders have been deeply affected by drug abuse, HIV/AIDS, and other infectious diseases in recent years, with new HIV infections continuing at an alarming rate in the U.S. and in other nations. There are an estimated 800,000 to 900,000 people living with HIV in the U.S., with approximately 40,000 new HIV infections occurring every year. By race, more than half of new HIV infections in 2001 and deaths attributable to AIDS in 2000 occurred among African Americans, although they represent only 13% of the U.S. population. This PA seeks to stimulate a range of investigator-initiated studies to advance the scientific knowledge base on drug abuse aspects of HIV/AIDS and other serious infections. Researchers are invited to address diverse and cross-cutting issues in multiple disciplines, including, among others: virology, bacteriology, molecular epidemiology, etiology, therapeutics and vaccines, ethnography and behavioral epidemiology, mathematical modeling and simulations, and the behavioral and social sciences.